Skip to main content
. 2019 Nov 15;20(22):5731. doi: 10.3390/ijms20225731

Table 2.

Main differences between uveal and cutaneous melanoma and their response to immunotherapy with check-point inhibitors.

UVEAL CUTANEOUS
606 cases/year in Europe 100,000 cases/year in Europe
Mainly liver metastasis Metastasis in various organs
GNAQ or GNA11 gene mutations BRAF or NRAS gene mutations
Monosomy 3 in 50% of tumors Monosomy 3 rarely occurring
0.8–5% positive responsiveness to immunotherapy 20–60% positive responsiveness to immunotherapy